What is Rdx Bioscience?
RDx Bioscience operates as an advanced CAP accredited and CLIA certified clinical diagnostic laboratory. The company is dedicated to supporting risk-bearing entities by providing comprehensive diagnostic testing and laboratory tools designed to achieve quality goals and improve patient outcomes. RDx Bioscience focuses on delivering personalized service, embracing continual innovation in testing, and offering access to the latest specialized clinical tests. Their service model is particularly geared towards confronting chronic diseases and supporting healthcare providers in adopting risk-based contracts that emphasize value through quality and clinical outcomes. The company also leverages proprietary algorithms to assist delegated medical groups, ACOs, Medicare STARs, MIPS, and state-based Medicaid incentive bonuses, aiming to reduce re-admissions and improve care coordination through advanced laboratory interventions.
How much funding has Rdx Bioscience raised?
Rdx Bioscience has raised a total of $1.8M across 2 funding rounds:
Debt
$1M
Debt
$750K
Debt (2020): $1M with participation from PPP
Debt (2021): $750K led by PPP
Key Investors in Rdx Bioscience
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for Rdx Bioscience?
With substantial enterprise-level funding and a recent strategic investment, RDx Bioscience is poised for significant expansion and continued innovation. The company's focus on supporting risk-bearing entities and its proprietary algorithms suggest a strategic direction towards enhancing value-based care models. Future developments are likely to involve scaling its diagnostic services, further refining its predictive analytics for chronic disease management, and potentially forging new partnerships within the healthcare ecosystem to solidify its competitive advantage in an evolving healthcare landscape.
See full Rdx Bioscience company page
